Effects of Canine-Obtained Lactic-Acid Bacteria on the Fecal Microbiota and Inflammatory Markers in Dogs Receiving Non-Steroidal Anti-Inflammatory Treatment.

Abstract

Simple SummaryThe use of non-steroidal anti-inflammatory drugs (NSAIDs) has prolonged the longevity and well-being of dogs with osteoarthritis and other painful conditions. However, this treatment is also associated with diarrhea in dogs, but the pathogenetic mechanisms and possible prevention strategies remain unknown. This study aimed to determine whether canine-obtained lactic acid bacteria affect the frequency of diarrhea, fecal microbiota (dysbiosis index), and gastrointestinal inflammation (assessed by calprotectin and S100A12/Calgranulin C) in dogs receiving NSAIDs. Diarrhea occurred in 4/12 dogs (33%) receiving placebo and 1/10 dogs (10%) receiving canine-obtained lactic acid bacteria (LAB), but this difference was not significant. The fecal dysbiosis index, calprotectin, and S100A12 were not significantly different between dogs receiving NSAIDs and LAB and dogs receiving NSAIDs and placebo. This study suggests that LAB is safe to use in NSAID-treated dogs, but further studies are needed to determine its potential to ameliorate diarrhea and gastrointestinal inflammation in dogs receiving NSAIDs.Non-steroidal anti-inflammatory drugs (NSAIDs) may cause enteropathy in dogs and probiotics may be one option to prevent this. The objective of this study was to determine whether the administration of canine-obtained lactic acid bacteria (LAB) has an effect on the frequency of diarrhea, the composition of the fecal microbiota, and/or markers of gastrointestinal inflammation in dogs receiving NSAIDs when compared to dogs given NSAIDs and a placebo. A total of 22 dogs treated with NSAIDs for various clinical indications were enrolled in a seven-day randomized, double-blinded placebo-controlled interventional study. Dogs were randomized to receive either placebo or LAB, a product containing Limosilactobacillus fermentum, Lacticaseibacillus rhamnosus, and Lactiplantibacillus plantarum. Fecal samples were collected on days one and seven. The fecal microbiota was evaluated using the fecal dysbiosis index (DI) and individual bacterial taxa. Fecal calprotectin (CP) and S100A12/Calgranulin C concentrations were used as markers of gastrointestinal inflammation. There was a difference in frequency of diarrhea between groups, with it affecting 4/12 dogs (33%) in the placebo group and 1/10 dogs (10%) in the LAB group, but this difference did not reach statistical significance (p = 0.32). There was a correlation between S100A12 and CP (p < 0.001), and Clostridium perfringens correlated with S100A12 (p < 0.015). Neither treatment significantly affected S100A12 (p = 0.37), CP (p = 0.12), or fecal DI (p = 0.65). This study suggests that LAB is a safe supplement to use for short-term treatment in NSAID-treated dogs, but further studies are needed to determine its potential to prevent NSAID-induced enteropathy in dogs.